MMP12 and ischemic stroke: Although this study has some limitations such as lack of experimentation that demonstrate the type of TUNEL positive cells, paucity of sufficient data on toxicity upon intravenous delivery of MMP-12 shRNA expressing plasmids which can lead to widespread expression changes and lack of clarity on the time point following ischemia at which MMP-12 activity is actually detrimental/beneficial, MMP-12 is regarded as a promising therapeutic target for ischemic stroke.